Mecanismo de acción y farmacocinética de agonista beta adrenérgico de efecto rápido (salbutamol) y atención farmacéutica dirigido al paciente asmático

Abstract

In this research, the mechanism of action and the pharmacokinetics of salbutamol are determined by reviewing various scientific articles for the development of a pharmaceutical care program for asthmatic patients. Asthma is a non-communicable chronic disease, it presents various episodes such as dyspnoea, cough, wheezing and chest tightness. To treat this type of pathology, drugs that belong to the family of beta 2 adrenergic receptor agonists are used, which are located in the bronchioles and smooth muscle. Within this group, salbutamol is found, it is used as a bronchodilator with a short half-life, it acts by relaxing the bronchial smooth muscles and prevents inflammation mediators such as mast cells from being released. The pharmacokinetics begins after its intravenous release, the absorption of small particles in the gastrointestinal tract occurs quickly and is later distributed in the systemic circulation and reaches the maximum plasma concentration, it is metabolized at the liver level and is eliminated in the urine. A file is presented that details the correct use of the nebulizer, the measures that help to identify an asthmatic patient and the nutritional recommendations that should be considered to avoid risk situations.